|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
87,040,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is engaged in developing and commercializing targeted therapies for patients with genomically-defined cancers. Co.'s main product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Co.'s second product candidate, pimasertib, is an oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the RAS/mitogen-activated protein kinase pathway.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
2,244,684 |
4,978,018 |
Total Buy Value |
$0 |
$0 |
$24,978,318 |
$65,978,328 |
Total People Bought |
0 |
0 |
1 |
3 |
Total Buy Transactions |
0 |
0 |
4 |
7 |
Total Shares Sold |
85,781 |
95,866 |
106,432 |
4,385,657 |
Total Sell Value |
$1,340,327 |
$1,458,221 |
$1,603,792 |
$59,625,737 |
Total People Sold |
4 |
4 |
4 |
8 |
Total Sell Transactions |
8 |
12 |
19 |
97 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Blackman Samuel C. |
HEAD OF R&D |
|
2024-04-18 |
4 |
AS |
$16.02 |
$160,163 |
D/D |
(10,000) |
1,174,662 |
|
- |
|
Blackman Samuel C. |
HEAD OF R&D |
|
2024-03-25 |
4 |
AS |
$16.01 |
$160,055 |
D/D |
(10,000) |
1,184,662 |
|
- |
|
Blackman Samuel C. |
HEAD OF R&D |
|
2024-03-11 |
4 |
AS |
$15.24 |
$457,314 |
D/D |
(30,000) |
1,194,662 |
|
- |
|
Blackman Samuel C. |
HEAD OF R&D |
|
2024-02-27 |
4 |
AS |
$16.11 |
$322,166 |
D/D |
(20,000) |
1,224,662 |
|
- |
|
York Charles N Ii |
COO, CFO AND SECRETARY |
|
2024-02-16 |
4 |
S |
$15.25 |
$40,651 |
D/D |
(2,666) |
277,754 |
|
- |
|
Dubow Adam |
GENERAL COUNSEL |
|
2024-02-16 |
4 |
S |
$15.25 |
$49,434 |
D/D |
(3,242) |
16,585 |
|
- |
|
Blackman Samuel C. |
HEAD OF RESEARCH AND DEVELOPME |
|
2024-02-16 |
4 |
S |
$15.25 |
$34,430 |
D/D |
(2,258) |
1,244,662 |
|
- |
|
Bender Jeremy |
CHIEF EXECUTIVE OFFICER |
|
2024-02-16 |
4 |
S |
$15.25 |
$116,114 |
D/D |
(7,615) |
721,813 |
|
- |
|
York Charles N Ii |
COO, CFO AND SECRETARY |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,250 |
280,420 |
|
- |
|
Dubow Adam |
GENERAL COUNSEL |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,399 |
19,827 |
|
- |
|
Blackman Samuel C. |
HEAD OF RESEARCH AND DEVELOPME |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,686 |
1,246,920 |
|
- |
|
Bender Jeremy |
CHIEF EXECUTIVE OFFICER |
|
2024-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,999 |
729,428 |
|
- |
|
Dubow Adam |
General Counsel |
|
2023-11-16 |
4 |
S |
$11.69 |
$62,109 |
D/D |
(5,313) |
11,428 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-11-16 |
4 |
S |
$11.69 |
$11,176 |
D/D |
(956) |
270,170 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-11-16 |
4 |
S |
$11.69 |
$36,321 |
D/D |
(3,107) |
709,429 |
|
- |
|
Blackman Samuel C. |
Head of Research and Developme |
|
2023-11-16 |
4 |
S |
$11.69 |
$8,288 |
D/D |
(709) |
1,238,234 |
|
- |
|
Dubow Adam |
General Counsel |
|
2023-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,600 |
16,741 |
|
- |
|
York Charles N Ii |
COO, CFO and Secretary |
|
2023-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,625 |
271,126 |
|
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,312 |
712,536 |
|
- |
|
Blackman Samuel C. |
Head of Research and Developme |
|
2023-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,624 |
1,238,943 |
|
- |
|
Dubow Adam |
General CounselOfficer |
|
2023-11-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,141 |
|
- |
|
Blavatnik Len |
Affiliate of 10% Owner |
|
2023-10-20 |
4 |
B |
$9.97 |
$1,110,907 |
D/D |
111,387 |
12,929,322 |
2.44 |
- |
|
Blavatnik Len |
Affiliate of 10% Owner |
|
2023-10-19 |
4 |
B |
$10.06 |
$3,867,372 |
D/D |
384,400 |
12,817,935 |
2.44 |
- |
|
Blavatnik Len |
Affiliate of 10% Owner |
|
2023-10-18 |
4 |
B |
$10.21 |
$10,000,049 |
D/D |
979,667 |
12,433,535 |
2.44 |
- |
|
Bender Jeremy |
Chief Executive Officer |
|
2023-08-17 |
4 |
S |
$13.86 |
$41,525 |
D/D |
(2,996) |
704,224 |
|
- |
|
168 Records found
|
|
Page 1 of 7 |
|
|